{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:28:34Z","timestamp":1792214914139,"version":"4.4.0"},"reference-count":36,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15309","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:01:11Z","timestamp":1759312871000},"page":"1-14","source":"Crossref","is-referenced-by-count":2,"title":["Application value and safety of trilaciclib in first\u2011line chemotherapy combined with immunotherapy for\u00a0 extensive\u2011stage small cell lung cancer: A real\u2011world study"],"prefix":"10.3892","volume":"30","author":[{"given":"Yanping","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, Chengde Central Hospital, Chengde, Hebei 067000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, Chengde Central Hospital, Chengde, Hebei 067000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, Chengde Central Hospital, Chengde, Hebei 067000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Lou","sequence":"additional","affiliation":[{"name":"Endoscopy Center, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"key20251111103841_b1-ol-30-6-15309","first-page":"620","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"key20251111103841_b2-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"key20251111103841_b3-ol-30-6-15309","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"key20251111103841_b4-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","article-title":"Molecular profiles of small cell lung cancer subtypes: Therapeutic implications","volume":"20","author":"Schwendenwein","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"key20251111103841_b5-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"key20251111103841_b6-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","article-title":"Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial","volume":"29","author":"Spigel","year":"2011","journal-title":"J Clin Onco"},{"key":"key20251111103841_b7-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"113581","DOI":"10.1016\/j.ejca.2024.113581","article-title":"Recent advances and future strategies in first-line treatment of ES-SCLC","volume":"200","author":"Gomez-Randulfe","year":"2024","journal-title":"Eur J Cancer"},{"key":"key20251111103841_b8-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1186\/s12885-024-12954-8","article-title":"Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): A multicenter, single-arm, phase II trial","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"key20251111103841_b9-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","article-title":"Overcoming chemotherapy resistance in SCLC","volume":"16","author":"Herzog","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20251111103841_b10-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"HSR25","DOI":"10.6004\/jnccn.2024.7175","article-title":"HSR25-156: Myelosuppression and healthcare resource utilization in community oncology patients with limited-stage small cell lung cancer (LS-SCLC) receiving first-line therapy with or without trilaciclib","volume":"23","author":"Gajra","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"key20251111103841_b11-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"e0219622","DOI":"10.1371\/journal.pone.0219622","article-title":"Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)","volume":"14","author":"Povsic","year":"2019","journal-title":"PLoS One"},{"key":"key20251111103841_b12-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv Ther"},{"key":"key20251111103841_b13-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1517\/14656566.3.9.1273","article-title":"G-CSF as prophylaxis of febrile neutropenia in SCLC","volume":"3","author":"Adams","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"key20251111103841_b14-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"key20251111103841_b15-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"e000847","DOI":"10.1136\/jitc-2020-000847","article-title":"CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy","volume":"8","author":"Lai","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20251111103841_b16-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s12325-023-02601-2","article-title":"Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy","volume":"40","author":"Goldschmidt","year":"2023","journal-title":"Adv Ther"},{"key":"key20251111103841_b17-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"1157251","DOI":"10.3389\/fphar.2023.1157251","article-title":"The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: A systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Qiu","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20251111103841_b18-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: A phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann Oncol"},{"key":"key20251111103841_b19-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"107455","DOI":"10.1016\/j.lungcan.2023.107455","article-title":"Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)","volume":"188","author":"Cheng","year":"2024","journal-title":"Lung Cancer"},{"key":"key20251111103841_b20-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1002\/cam4.4089","article-title":"Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials","volume":"10","author":"Ferrarotto","year":"2021","journal-title":"Cancer Med"},{"key":"key20251111103841_b21-ol-30-6-15309","first-page":"3793","article-title":"Objective assessment of WHO\/ECOG performance status","volume":"10","author":"Sok","year":"2019","journal-title":"Support Care Cancer"},{"key":"key20251111103841_b22-ol-30-6-15309","first-page":"3669","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): A systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"key":"key20251111103841_b23-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1177\/1740774518799985","article-title":"Patient-reported outcomes version of the common terminology criteria for adverse events: Methods for item selection in industry-sponsored oncology clinical trials","volume":"15","author":"Trask","year":"2018","journal-title":"Clin Trials"},{"key":"key20251111103841_b24-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20251111103841_b25-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20251111103841_b26-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7150\/jca.55159","article-title":"The association between pretreatment anemia and overall survival in advanced non-small cell lung cancer: A retrospective cohort study using propensity score matching","volume":"13","author":"Huang","year":"2022","journal-title":"J Cancer"},{"key":"key20251111103841_b27-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"790051","DOI":"10.3389\/fimmu.2021.790051","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: Case report and literature review","volume":"12","author":"Xie","year":"2021","journal-title":"Front Immunol"},{"key":"key20251111103841_b28-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12885-021-08384-5","article-title":"A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: A large population-based study","volume":"21","author":"Shan","year":"2021","journal-title":"BMC Cancer"},{"key":"key20251111103841_b29-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jtho.2022.05.016","article-title":"Brief report: Exploratory analysis of maintenance therapy in patients with extensive-stage SCLC treated first line with atezolizumab plus carboplatin and etoposide","volume":"17","author":"Reck","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20251111103841_b30-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"17464","DOI":"10.1038\/s41598-023-42725-7","article-title":"A nomogram for predicting severe myelosuppression in small cell lung cancer patients following the first-line chemotherapy","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"key20251111103841_b31-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41401-024-01297-6","article-title":"Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: A pooled pharmacometrics analysis","volume":"45","author":"Dai","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"key20251111103841_b32-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/ijc.33453","article-title":"Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled phase II trial","volume":"148","author":"Daniel","year":"2021","journal-title":"Int J Cancer"},{"key":"key20251111103841_b33-ol-30-6-15309","first-page":"100869","article-title":"Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"key20251111103841_b34-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat Med"},{"key":"key20251111103841_b35-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.3390\/ijms20194931","article-title":"Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer","volume":"20","author":"Bianco","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20251111103841_b36-ol-30-6-15309","doi-asserted-by":"publisher","first-page":"e32907","DOI":"10.1016\/j.heliyon.2024.e32907","article-title":"Exploring the prognostic impact of differences in treatment strategies for SCLC with different histologies and prognostic factors for C-SCLC: A SEER population-based study","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:38:48Z","timestamp":1762850328000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15309","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}